WebAmacaThera 1.181 seguidores no LinkedIn. Transforming therapeutics to make a difference in patient health AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world … WebCo-founded in 2016 by Dr. Molly Shoichet and Dr. Mike Cooke, AmacaThera was spun out of Shoichet’s University of Toronto laboratory through the UTEST accelerator to commercialize novel hydrogels. The company’s lead product, AMT-143, aims to improve post-operative pain management with potential applicability to any surgical incision.
Amacathera - Overview, News & Competitors ZoomInfo.com
Web20 okt. 2024 · TORONTO, Oct. 20, 2024 /PRNewswire – AmacaThera Inc. is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead … Web22 feb. 2024 · February 22, 2024 AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical … the hermitage rockingham nc
Mike Cooke, CEO at Amacathera
Web3 okt. 2024 · AmacaThera's first product, AMT-143, is being developed to improve post-operative pain control thereby reducing or eliminating opioid use following surgery. Mike Cooke, AmacaThera's Co-Founder and CEO added, … WebDr. Mike Cooke co-founded AmacaThera Inc. with Dr. Molly Shoichet in 2016 to commercialize novel hydrogels. The Toronto-based company is developing a pipeline of … Web22 feb. 2024 · “AmacaThera’s lead product will be a great option for patients in the treatment of post-surgical pain,” said Mike Serrano-Wu, ... Michael Cooke, CEO and cofounder of AmacaThera, ... the hermitage resort virginia